CLINICAL_TRIALS
trial_result
· 2021-06-07
Clinical Trial Update: Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults [Phase 3]
Summary
Phase 3 trial update on immunogenicity and safety of the tetravalent dengue vaccine (TDV) at end of shelf life in healthy adults.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Dengue Fever | Phase 3 | Status: COMPLETED | Results posted: 2021-06-07